Celcuity Completes $575M Convertible Note Offering at 40% Premium, Repays $137.5M Debt
Summary
Celcuity completed an upsized $575 million convertible senior note offering with a 40% conversion premium, generating $557 million in net proceeds, and used $137.5 million to repay existing debt, significantly bolstering its financial position for upcoming clinical and commercial milestones.
Key Events
-
Upsized Convertible Note Offering Completed
Celcuity successfully closed an upsized public offering of $575 million aggregate principal amount of 0.250% Convertible Senior Notes due 2032, including the full exercise of the over-allotment option.
-
Significant Net Proceeds
The offering generated approximately $557.0 million in net proceeds for the company.
-
Favorable Conversion Premium
The notes were priced with an initial conversion price of $124.53 per share, representing a 40.0% premium over the stock's closing price on June 3, 2026 ($88.95).
-
Debt Repayment
The company used $137.5 million of the proceeds to fully repay and terminate an existing Amended and Restated Loan and Security Agreement, improving its balance sheet.
Analysis
This 8-K announces the successful completion of an upsized $575 million convertible senior note offering, generating $557 million in net proceeds. The offering was priced at a 40% conversion premium to the stock's closing price on June 3, 2026, indicating strong investor confidence in the company's future growth despite recent stock volatility. A significant portion of the proceeds, $137.5 million, was used to repay existing debt, strengthening the balance sheet. The remaining capital will fund critical clinical trials and commercialization efforts for its lead therapeutic candidate, gedatolisib, which has an upcoming FDA PDUFA date of July 17, 2026. This financing provides substantial financial runway for Celcuity's strategic initiatives.
At the time of this filing, CELC was trading at $87.43 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $11.28 to $151.02. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.